Intelligence Feed event · Equity · 2026-09-21

    Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue Following 153% EPS Surge

    Question

    Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue Following 153% EPS Surge

    Direct answer

    Bristol Myers Squibb is demonstrating operational progress in managing major patent expirations, supported by second-quarter revenue of $12.9 billion and a 153% surge in earnings per share. The stock has advanced 17% year-to-date. Crucially, the company growth portfolio consisting of recently launched treatments posted 15% year-over-year revenue expansion, reaching approximately 60% of total corporate sales and providing visibility on sustainable top-line replacement.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-21
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue Following 153% EPS Surge”, revision 1, evidence through 2026-09-21. https://marketontology.com/market-events/2026-09-21/bristol-myers-squibb-growth-portfolio-reaches-60-of-revenue-following-153-eps-su-cecf1b

    EQUITY
    Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue Following 153% EPS Surge
    Bristol Myers Squibb is demonstrating operational progress in managing major patent expirations, supported by second-quarter revenue of $12.9 billion and a 153% surge in earnings per share. The stock has advanced 17% year-to-date. Crucially, the company growth portfolio consisting of recently launched treatments posted 15% year-over-year revenue expansion, reaching approximately 60% of total corporate sales and providing visibility on sustainable top-line replacement.
    BMYABBV
    Impact
    66
    SEP 21
    SIG
    84%
    BMYABBV
    Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue Following 153% EPS Surge
    Bristol Myers Squibb is demonstrating operational progress in managing major patent expirations, supported by second-quarter revenue of $12.9 billion and a 153% surge in earnings per share. The stock has advanced 17% year-to-date. Crucially, the company growth portfolio consisting of recently launched treatments posted 15% year-over-year revenue expansion, reaching approximately 60% of total corporate sales and providing visibility on sustainable top-line replacement.
    → A 15% expansion in high-margin growth therapies to 60% of product mix offsets legacy patent cliff revenue loss, driving P/E multiple rerating for BMY.
    Impact
    Bristol Myers Squibb is demonstrating operational progress in managing major patent expirations, supported by second-quarter revenue of $12.9 billion and a 153% surge in earnings per share. The stock has advanced 17% year-to-date. Crucially, the company growth portfolio consisting of recently launched treatments posted 15% year-over-year revenue expansion, reaching approximately 60% of total corporate sales and providing visibility on sustainable top-line replacement.
    Affected
    BMYABBV
    Transmission
    A 15% expansion in high-margin growth therapies to 60% of product mix offsets legacy patent cliff revenue loss, driving P/E multiple rerating for BMY.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    BMYearnings multiple expansion on replacement of mature drug revenues by new growth therapiesUp1-4wSource reports Q2 revenue of $12.9B, 153% EPS growth, and growth portfolio representing nearly 60% of sales.
    ABBVpeer valuation benchmarking for post-patent transition biopharma namesWatch1-4wAbbVie is a primary large-cap peer navigating post-patent cliff revenue transitions.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month